anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A prospective, multicenter, post-market, minimal risk, observational study designed to collect up to 60 PillCamTM SB3 CE procedures and subsequent DAE procedures data (double balloon enteroscopy (DBE), single balloon enteroscopy (SBE) and spiral enteroscopy (SE)) in up to 6 medical centers in the United States (US). The data will be collected from subjects who underwent standard of care (SOC) PillCamTM SB3 CE procedure and were referred to a subsequent SOC DAE. In addition, relevant surgical, endoscopic and histology reports as well as radiological data (such as CT, Magnetic Resonance Enterography (MRE) images and reports) may be collected retrospectively 6 months prior to enrollment and prospectively 3 months post enrollment, when applicable. In addition, up to 400 PillCamTM SB3 CE procedures data may be collected from subjects who underwent SB3 procedure (not necessarily followed by DAE) and abnormal SB findings were indicated in their CE report. Study duration is up to 3 years from initial Institutional Review Board (IRB) approval.

Collected data will include PillCamTM raw data, videos and reports, as well as DAE reports, videos and histology reports (when applicable). Demographic data will also be collected to provide a description of the study population characteristics and disposition. All the collected data will be de-identified by delegated and authorized sites' team members, in a manner that is untraceable by the sponsor. The data will be used by Medtronic Gastrointestinal research and development (R\&D) team in collaboration with third parties, including but not limited to external physicians and R\&D partners, as applicable, for development of an Artificial Intelligence (AI) software system to apply to endoscopy procedures, as well as for SB pathologies detection development and validation.
ABSTRACT OF THE DISCLOSURE           Substituted 3-amino-sydnone-imines having the general formula:                             (I) and pharmacologically acceptable acid addition salts thereof, wherein R1 denotes hydrogen or halogen, R2 denotes hydrogen, -NO or a -COR3 or -SO2R4 group, R3 denotes hydrogen, an aliphatic radical, a cycloaliphatic radical, an aryl radical, an araliphatic radical, an alkoxy radical, an aryloxy radical, a five-membered or six-membered hetero-aromatic radical or an alkoxycarbonyl radical, A denotes the group  , in which m is 0, 1 or 2, or the group  , R4 and R5 independently of one another denote an aliphatic radical, an aryl radical, or a dialkylamino group, are prepared by optionally cyclising a compound of the general formula II                                          (II) to give a compound of the general formula Ia, which can also be present in the form of an acid addition salt,                                (Ia) and optionally, a.) acylating the resulting compound Ia or its acid addition salt with acylating agents introducing the radical -COR3 or -SO2R4 or nitrosating the resulting compound Ia or its acid addition salt, and/or optionally b.) halogenating the resulting compound Ia or its acid addition salt with halogen or halogenating agents whereby the optional steps a.) and b.) are carried out in any order, and the compound thus obtained is optionally converted to the acid addition salt.  The novel compounds and their salts have beneficial and improved effects on the cardio-vascular system, for example, by lowering blood pressure, the pulmonary artery pressure and the left vertricular enddiastolic pressure, thus reducing the cardiac work in the sense of an anti-anginal action without provoking refluxtachycardia.
The fascia of the pancreatic head is referred to as the retropancreatic fascia of Treitz, and that of the body and tail of the pancreas is named the retropancreatic fascia of Toldt. However, the spatial relationship between the nerves, fascia, and the distribution of the fascia on the dorsal side of the pancreas remains unclear. Therefore, this study aimed to explore the distribution of these fasciae and elucidate the spatial relationship between the nerves and arteries connecting the retroperitoneal space and the peritoneal organs by studying eight cadavers using macroscopic anatomical examination, wide-range serial sectioning, and three-dimensional reconstruction. The fasciae of Treitz and Toldt converge caudally to the root of the superior mesenteric artery (SMA), forming a narrower gap around the roots of the celiac trunk and SMA than in the celiac plexus. The fasciae eventually get closer to each other, and the boundary between them becomes obscured, providing coverage to the anterior surface of the aorta between the SMA and the inferior mesenteric artery. The celiac plexus does not penetrate the fascia but converges before spreading into the pancreas. Similarly, the arteries pass through this gap in the fasciae. Our findings suggest that the retroperitoneal space and peritoneal organs are connected through a narrow no-fascia area, with the distribution of the fascia relating to nervous and vascular pathways. Our findings reveal that the distribution of the avascular plane may provide a crucial anatomical foundation for abdominal digestive organ surgery by reducing bleeding volume and determining the dissection region.
Muscle ultrasound has been shown to be a valid and safe imaging modality to assess muscle wasting in critically ill patients in the intensive care unit (ICU). This typically involves manual delineation to measure the rectus femoris cross-sectional area (RFCSA), which is a subjective, time-consuming, and laborious task that requires significant expertise. We aimed to develop and evaluate an AI tool that performs automated recognition and measurement of RFCSA to support non-expert operators in measurement of the RFCSA using muscle ultrasound. Twenty patients were recruited between Feb 2023 and July 2023 and were randomized sequentially to operators using AI (n = 10) or non-AI (n = 10). Muscle loss during ICU stay was similar for both methods: 26 ± 15% for AI and 23 ± 11% for the non-AI, respectively (p = 0.13). In total 59 ultrasound examinations were carried out (30 without AI and 29 with AI). When assisted by our AI tool, the operators showed less variability between measurements with higher intraclass correlation coefficients (ICCs 0.999 95% CI 0.998-0.999 vs. 0.982 95% CI 0.962-0.993) and lower Bland Altman limits of agreement (± 1.9% vs. ± 6.6%) compared to not using the AI tool. The time spent on scans reduced significantly from a median of 19.6 min (IQR 16.9-21.7) to 9.4 min (IQR 7.2-11.7) compared to when using the AI tool (p < 0.001). AI-assisted muscle ultrasound removes the need for manual tracing, increases reproducibility and saves time. This system may aid monitoring muscle size in ICU patients assisting rehabilitation programmes.
The invention disclose an aspirin enteric-coated tablet applied in the technical field of medicine preparations and a preparation technology thereof. The enteric-coated tablet comprises a tablet core and an enteric coating layer. The tablet core comprises aspirin, a filling agent, an adhesive and a glidant. The enteric coating layer comprises an enteric material, a plasticizer, an antiadherent and water. The preparation technology includes mixing blank accessories, granulating the mixed blank accessories and drying to obtain accessory particles, mixing the aspirin and the accessory particles to obtain a totally-mixed particles; subjecting the totally-mixed particles to dry granulation to obtain intermediate particles, tabletting the intermediate particles, coating the tablet core obtained after tabletting to prepare the enteric-coated tablet, and drying the enteric-coated tablet in air. According to the tablet and the preparation technology, aqueous dispersion film is adopted for coating, thus solving latent risks of solvent residue and capability of being flammable and combustible which are produced by coating dissolution by organic solvents. The blank accessories are granulated in a wet method, thus overcoming sticky punch and tablet weight difference over-limit which are caused by tabletting in large batches and for a long time.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver condition that often progresses to more advanced stages, such as metabolic dysfunction-associated steatohepatitis (MASH). MASH is characterized by inflammation and hepatocellular ballooning, in addition to hepatic steatosis. Despite the relatively high incidence of MASH in the population and its potential detrimental effects on human health, this liver disease is still not fully understood from a pathophysiological perspective. Deregulation of polyamine levels has been detected in various pathological conditions, including neurodegenerative diseases, inflammation, and cancer. However, the role of the polyamine pathway in chronic liver disorders such as MASLD has not been explored. In this study, we measured the expression of liver ornithine decarboxylase (ODC1), the rate-limiting enzyme responsible for the production of putrescine, and the hepatic levels of putrescine, in a preclinical model of MASH as well as in liver biopsies of patients with obesity undergoing bariatric surgery. Our findings reveal that expression of ODC1 and the levels of putrescine, but not spermidine nor spermine, are elevated in hepatic tissue of both diet-induced MASH mice and patients with biopsy-proven MASH compared with control mice and patients without MASH, respectively. Furthermore, we found that the levels of putrescine were positively associated with higher aspartate aminotransferase concentrations in serum and an increased SAF score (steatosis, activity, fibrosis). Additionally, in in vitro assays using human HepG2 cells, we demonstrate that elevated levels of putrescine exacerbate the cellular response to palmitic acid, leading to decreased cell viability and increased release of CK-18. Our results support an association between the expression of ODC1 and the progression of MASLD, which could have translational relevance in understanding the onset of this disease. © 2024 The Pathological Society of Great Britain and Ireland.
It has been argued that experiencing the pain of others motivates helping. Here, we investigate the contribution of somatic feelings while witnessing the pain of others onto costly helping decisions, by contrasting the choices and brain activity of participants that report feeling somatic feelings (self-reported mirror-pain synesthetes) against those that do not. Participants in fMRI witnessed a confederate receiving pain stimulations whose intensity they could reduce by donating money. The pain intensity could be inferred either from the facial expressions of the confederate in pain (Face condition) or from the kinematics of the pain-receiving hand (Hand condition). Our results show that self-reported mirror-pain synesthetes increase their donation more steeply, as the intensity of the observed pain increases, and their somatosensory brain activity (SII and the adjacent IPL) was more tightly associated with donation in the Hand condition. For all participants, activation in insula, SII, TPJ, pSTS, amygdala and MCC correlated with the trial by trial donation made in the Face condition, while SI and MTG activation was correlated with the donation in the Hand condition. These results further inform us about the role of somatic feelings while witnessing the pain of others in situations of costly helping.
Schistosomiasis afflicts approximately 120 million individuals globally. The hepatic pathology that occurs due to egg-induced granuloma and fibrosis is commonly attributed to this condition. However, there is currently no efficacious treatment available for either of these conditions.Our study aimed to investigate the potential antifibrotic and antiparasitic properties of different doses of gallic acid (GA) in experimental schistosomiasis mansoni. In addition, we investigated the outcomes of co-administering it with the standard anti-schistosomiasis treatment, praziquantel (PZQ).In experiment I, Schistosoma mansoni-infected mice were administered GA at doses of 10, 20, or 40 mg/kg. Their effectiveness was evaluated through parasitological (worm and egg loads, granuloma number and diameter), pathological (fibrosis percentage and H-score of hepatic stellate cells (HSCs)), and functional (liver enzymes) tests. In experiment II, we investigated the optimal dosage that yielded the best outcomes. This dosage was administered in conjunction with PZQ and was evaluated regarding the parasitological, pathological, functional, and immunological (fibrosis-regulating cytokines) activities.Our findings indicate that the administration of 40 mg/kg GA exhibited the highest level of effectiveness in experiment I. In experiment II, it exhibited lower antiparasitic efficacy in comparison to PZQ. However, it surpassed PZQ in other tests. It showed enhanced outcomes when combined with PZQ.In conclusion, our findings reveal that GA only slightly increased the antischistosomal activity of PZQ. However, it was linked to decreased fibrosis, particularly when administrated with PZQ. Our pilot study identifies GA as a natural antifibrotic agent, which could be administered with PZQ to mitigate the development of fibrosis.
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to the pharmaceutical industry, in particular to an oral laxative pharmaceutical composition comprising (based on weight of composition): 30–55 wt. % of anhydrous macrogol; 45–70 wt. % of a carrier with a melting point of 36–38 °C, consisting of an anhydrous hydrophobic lipid shell consisting of a fatty compound of vegetable origin; up to 5 wt. % of at least one additive selected from diluting agents, agents for improving homogeneity of the composition, sweeteners, flavouring agents and/or emulsifiers, wherein said shell consists of: either up to 100 wt. % shea butter, cocoa butter or mixture thereof, or 12–25 wt. % vegetable wax and 25–88 wt. % vegetable oil, controlling the melting temperature of carrier to 36–38 °C. Also disclosed are use of said carrier and a method of treating constipation in adults by administering said composition with dosage of anhydrous macrogol 5 to 15 g a day.EFFECT: group of inventions provides reducing the administered macrogol doses and thereby reducing the undesirable side effects while maintaining good effectiveness.12 cl, 10 tbl
Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
The invention discloses a traditional Chinese medicine of Chinese angelica and lumbricus pill for treatment of trigeminal neuralgia , and mainly helps to solve problems of existing western medicine using for treatment of trigeminal neuralgia that: the curative effect is poor and side-effects also exist. The traditional Chinese medicine is produced by the following steps: taking 30g radix astragali, 30g Chinese angelica, 30g ligusticum wallichii, 30g lumbricus and 15g asarum herb; grinding the ingredients above into fine powders; and then making the powders into honeyed pills with honey as an adhesive. Each pill is 6g. Dosage and administration are that: one pill each time, and three times a day. The pills are taken with boiled water. One treatment course takes 30 days. Effective rate for treatment of trigeminal neuralgia is 95% or more, and cure rate is 80% or more. The traditional Chinese medicine has no toxic or side effects.
Clomipramine hydrochloride capsules, USP are an antiobsessional drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. Clomipramine hydrochloride is available as capsules of 25, 50, and 75 mg for oral administration.

Clomipramine hydrochloride, USP is 3-chloro-5-[3-(dimethylamino)propyl]-10, 11-dihydro 5 Hdibenz[ b, f] azepine monohydrochloride, and its structural formula is: 

Clomipramine hydrochloride, USP is a white or slightly yellow crystalline powder that is slightly hygroscopic. It is freely soluble in water and in methylene, soluble in alcohol, and practically insoluble in ethyl ether and in hexane.

Each capsule contains clomipramine hydrochloride USP, 25 mg or 50 mg or 75 mg and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate and pre-gelatinized starch. Additionally, the hard gelatin capsule shell contains: D&C Yellow No. 10, FD&C Red No. 40 (25 mg capsules only), FD&C Blue No. 1(50 mg capsules only), gelatin, titanium dioxide and purified water. Each capsule is imprinted with black pharmaceutical ink which contains black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution.

FDA approved dissolution specifications differ from the USP dissolution specifications.
Disclosed and described systems, methods, and apparatus provide diagnostic display and analysis of patient data. An example radiology desktop system includes a workload manager that organizes and displays one or more worklists. The example workload manager retrieves and displays, based on receiving a selection of an active worklist, one or more exams associated with the active worklist. The example system includes a diagnostic hub triggered based on selection of an exam. The example diagnostic hub generates an exam preview panel provides a summary of the selected exam. The example diagnostic hub facilitates comparison, based on selection of a comparison exam via the user interface from a patient library, between the selected exam and the comparison exam via the diagnostic hub. The example diagnostic hub updates a worklist entry for the selected exam based on an analysis resulting from the comparison between the selected exam and the comparison exam.
BACKGROUND: Anticholinergic toxicity is commonly encountered in the emergency department. However, the availability of physostigmine, a central acetylcholinesterase inhibitor used to reverse anticholinergic delirium, has been significantly limited due to national drug shortages in the United States. Several articles have explored the viability of rivastigmine as an alternative treatment in these patients.
CASE REPORT: A 33-year-old man presented to the emergency department after a suspected suicide attempt. The patient was found with an empty bottle of diphenhydramine at the scene. On arrival, he was tachycardic and delirious, with dilated and nonreactive pupils and dry skin. As the clinical picture was highly suggestive of anticholinergic toxicity, the patient was treated with oral rivastigmine at a starting dose of 4.5 mg to reverse his anticholinergic delirium. Although a repeat dose was required, his delirium resolved without recurrence. Why Should an Emergency Physician Be Aware of This? Oral rivastigmine has been applied successfully here and in other case reports to reverse anticholinergic delirium with the benefit of prolonged agitation control. Emergency physicians may consider this medication in consultation with a specialist, with initial doses starting at 4.5-6 mg, if encountering anticholinergic delirium when physostigmine is not available.
Antimicrobial resistance (AMR) to extended spectrum cephalosporins (ESC) among Neisseria gonorrhoeae (Ng) is a major public health concern. With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. This project aims to identify new treatment modalities for uncomplicated gonorrhoea using the registered drugs ertapenem, fosfomycin and gentamicin. This trial is a double blind randomized clinical non-inferiority trial with four treatment arms. 108 participants are randomly assigned to each study arm . Participants will receive either ceftriaxone 500mg intramuscularly (IM) or ertapenem 1000mg IM or gentamicin 5mg/kg IM with a maximum of 400mg (in two doses) supplemented with an oral placebo, or receive fosfomycin 6g oral suspension supplemented with an intramuscular placebo. The bacterial eradication capacity of the study antimicrobials at the included infection site is measured 7-14 days after treatment, using an RNA-based Nucleic Acid Amplification Test (NAAT).

\*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.
Materials and Methods: A randomized, double-blind clinical trial with 75 participants was conducted. Participants were randomly assigned using block randomization in five groups: HOCl 0.025% and 0.05%, CHX 0.12 and 0.2% and sterile water as placebo. Participants were instructed to use each rinse with 10 ml of each solution for 30 seconds after dental prophylaxis. Samples of saliva were taken at baseline and after 30 seconds, 1, 3.5 and 7 hours to assess substantivity establishing the bacterial viability by the fluorescence method with the SYTO 9/propidium iodide dual staining. All participants were assessed with the Turesky visible plaque index at baseline and at 7 hours and adverse events were assessed. For the comparisons of the viability of the different rinses between times, the statistical test of generalized linear mixed model \[GT1\] adjusted to treatment, time and treatment-time interaction was used.